首页> 外文期刊>Npj - Primary Care Respiratory Medicine >Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study
【24h】

Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study

机译:一项由意大利医生进行的三重吸入疗法治疗的新诊断COPD患者的特征

获取原文
           

摘要

Factors predicting prescriptions of triple therapy were investigated in a large group of general practitioners in Italy. In the population treated by identified general practitioners, a cohort of newly diagnosed chronic obstructive pulmonary disease patients was extracted from IMS Health Longitudinal Database during the period 2010鈥?013. From the diagnosis, 1-year follow-up was evaluated. Thirty-two thousand forty-six newly diagnosed chronic obstructive pulmonary disease patients were evaluated (57.7% male, mean age 67 years). During 2 years prior to diagnosis less than 13% of patients were requested with a pulmonology evaluation and less than 5% with a spirometry; 65.1% cases were prescribed with a respiratory drug, which in 9.6% of cases was inhaled corticosteroid/long-acting 尾2-agonist fixed-dose combination. Two thousand and twenty eight patients (6.3% of the newly diagnosed chronic obstructive pulmonary disease patients) were treated with triple therapy during the first year of follow-up, whose 858 (42.3%) starting immediately, and 762 (37.6%) following an initial treatment with inhaled corticosteroid/long-acting 尾2-agonist fixed-dose combination. Being older, being requested with pulmonologist evaluation or spirometry, being prescribed with a inhaled corticosteroid/long-acting 尾2-agonist fixed-dose combination at diagnosis resulted independent predictors of triple therapy use.
机译:在意大利的一大批全科医生中,研究了预测三联疗法处方的因素。在已确定的全科医生治疗的人群中,从2010-013期间的IMS Health纵向数据库中提取了一批新诊断的慢性阻塞性肺疾病患者。从诊断开始,评估了1年的随访。评价了3.24万名新诊断的慢性阻塞性肺疾病患者(男性57.7%,平均年龄67岁)。在诊断之前的2年中,要求进行肺病学评估的患者少于13%,通过肺活量测定的患者少于5%; 65.1%的患者开了呼吸道药物,其中9.6%的患者服用了皮质类固醇/长效β2-激动剂固定剂量组合。在随访的第一年中,对28例患者(占新诊断的慢性阻塞性肺疾病患者的6.3%)进行了三联治疗,其中858例(42.3%)立即开始治疗,762例(37.6%)接受随访。吸入糖皮质激素/长效β2-激动剂固定剂量联合用药的初步治疗。在诊断时要求肺病学家评估或肺活量测定法年龄较大,并在诊断时开具吸入性糖皮质激素/长效β2-激动剂固定剂量联合用药,这是使用三联疗法的独立预测因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号